The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    July 2020

  • Pages
    323

  • View Count
    814

Example Insights

Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Context Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Industry-and-non-industry-players Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Grid-Analysis
Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Partnerships-and-Collaborations Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Competitiveness-Analysis Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Case-Study
Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Future-forecast Nuclear-Medicine-and-Radiopharmaceuticals-Manufacturing-Market-Segments  

 

Overview

Since the discovery of the means to artificially synthesize radioisotopes (early 1930s), they were almost immediately adopted for healthcare applications, by the mid-1940s. Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals. Despite their inherent toxicity, nuclear medicine is considered an important part of modern healthcare, with applications spanning across a number of therapeutic areas, including infectious diseases, immunological disorders, gastroenteric disease, cardiological disorders, oncological disorders, neurological disorders, and even certain psychiatric conditions. According to an article published by World Nuclear Association in May 2020, more than 10,000 hospitals worldwide claim to be using radioisotopes for various medical procedures; interestingly, of the aforementioned applications, 90% were reported to be related to disease diagnosis Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). It is worth highlighting that around 40 million diagnostic procedures, involving the use of the radioisotope Tc-99m alone, are conducted worldwide annually. Further, the introduction of the concept of theranostics, which involves the use of a single active ingredient for both diagnostic and therapeutic purposes, has opened up a new dimension of applications for nuclear medicine.

Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication. As a result, the demand for such specialized chemicals has grown at an exponential rate. However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise. Therefore, acquiring the necessary technical acumen and infrastructure to support such operations is not a feasible option for pharmaceutical companies, owing to a number of associated clauses and concerns (such as need for high capital investments, unique operating licenses and compliance to special regulatory requirements). Currently, stakeholders in the pharmaceutical industry primarily rely on suppliers and contract manufacturers to fulfill their radiopharmaceutical procurement needs. Moreover, there are a number of specialty service providers that claim to be engaged in this field, offering a variety of radioisotopes and affiliated services for healthcare applications. As more applications are discovered, the demand for nuclear material suppliers and service providers is likely to increase. This, coupled to the anticipated advances in the field of radiopharmaceuticals, affiliated technologies and products, is expected to offer lucrative opportunities to the contract service providers that are engaged in this domain.

Scope Of the Report

The ‘Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030’ report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered. 
  • An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size. 
  • Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement,  application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents. 
  • A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the radiopharmaceutical manufacturing market, over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (cardiology, neurology, oncology, thyroid and others), [B] application area (diagnostic and therapeutic) and [C] type of diagnostic radiopharmaceuticals (PET and SPECT), [D] type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), [E] purpose of production (in-house / outsourcing) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (arranged in the order of participant’s designation): 

  •     James Davis (Vice President Quality / R&D, Shertech Laboratories)
  •     Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina Medical School)
  •     Jan Pruim (Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen)
  •     Michael van Dam (Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology)
  •     Anonymous (ITM Isotopen Technologien München)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in the nuclear medicine and radiopharmaceutical manufacturing market?
  • For which application and disease indications are the radiopharmaceuticals being manufactured?
  • What are the various type of radionuclides being manufactured for the formulation of radiopharmaceuticals?
  • What is the relative competitiveness of manufacturers involved in the nuclear medicine and radiopharmaceutical manufacturing?
  • Which partnership models are commonly adopted by the radiopharmaceutical manufacturers in this industry?
  • What is the supply chain process for medical isotope Mo-99 / Tc-99m?
  • What are the key factors that are likely to influence the evolution of the nuclear medicine and radiopharmaceutical manufacturing market?         
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of nuclear medicine and radiopharmaceutical manufacturing market, in the short to mid and long term.

Chapter 3 provides a general introduction and a brief historical background of nuclear medicines and radiopharmaceuticals. It includes details on the applications of radiopharmaceuticals in the medical field, as well as various methods adopted by manufacturers for the production of radiopharmaceuticals. It also highlights the guidelines laid down by regulatory authorities for the production, packaging, labelling and storage, of radiopharmaceuticals. In addition, it features a discussion on the need for outsourcing in this field. Further, it presents the key requisites for the selection of a CMO partner and key future perspectives related to the use of radiopharmaceuticals within the nuclear medicine industry.

Chapter 4 provides a detailed overview of around 60 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of radiopharmaceuticals. The chapter provides details on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.

Chapter 5 provides an overview of around 70 non-industry players (academia and research institutes) that are actively involved in the production of radiopharmaceuticals. The chapter provides details on the year of establishment, purpose of production (fulfilling in-house requirements / for contract services), location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT) and type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others).

Chapter 6 features tabulated profiles of the mid-large sized US based contract service providers / in-house manufacturers that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook..

Chapter 7 features tabulated profiles of the large EU based contract service providers / in-house manufacturers that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook.

Chapter 8 features tabulated profiles of the mid-large sized contract service providers / in-house manufacturers based in Asia-Pacific and rest of the world, that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook.

Chapter 9 features a four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, the scale at which they manufacture their respective products and company size. 

Chapter 10 features an analysis of recent partnerships and collaborations inked in this domain, since 2017. It includes a brief description of the partnership models (including manufacturing / supply agreement, acquisition / merger, product development agreement and commercialization agreement, R&D agreement, licensing agreement, asset acquisition, distribution agreement, clinical trial agreement, process development agreement and others) that have been adopted by the stakeholders in this domain. It also includes the analysis based on various parameters such as year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement and  application of the radioisotope mentioned in the agreement. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 presents a detailed discussion on the supply chain model of medical isotope Mo-99 / Tc-99m, highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.

Chapter 12 presents an informed estimate of the current and future opportunity in the nuclear medicine and radiopharmaceutical manufacturing market, highlighting the likely growth of the market till the year 2030. The chapter presents a detailed market segmentation on the basis of target therapeutic area (cardiology, nephrology, oncology, thyroid and others), application area (diagnostic and therapeutic), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), purpose of production (in-house / outsourcing) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). 

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (arranged in the order of participant’s designation) James Davis (Vice President Quality / R&D, Shertech Laboratories), Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina Medical School), Jan Pruim (Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen), Michael van Dam (Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology) and Anonymous (ITM Isotopen Technologien München). 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Nuclear Medicines and Radiopharmaceuticals
3.3. Historical Evolution of Radiopharmaceuticals
3.4. Applications of Radiopharmaceuticals
3.4.1. Nuclear Imaging / Diagnosis
3.4.1.1. Single Photon Emission Computed Tomography
3.4.1.2. Positron Emission Tomography
3.4.2. Therapeutic Use

3.5. Production of Radiopharmaceuticals
3.5.1. Radionuclide Generator
3.5.2. Particle Accelerator (Cyclotron)
3.5.3. Nuclear Reactor

3.6. Regulatory Framework for Radiopharmaceuticals
3.6.1. Guidelines for the Production of Radiopharmaceuticals
3.6.2. Guidelines for Labelling and Packaging of Radiopharmaceuticals
3.6.3. Guidelines for Storage of Radiopharmaceuticals

3.7. Need for Outsourcing Radiopharmaceuticals Manufacturing
3.8. Selecting a CMO Partner for Radiopharmaceuticals Manufacturing
3.9. Current Scenario and Future Prospects Related to Radiopharmaceuticals

4. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Production
4.2.4. Analysis by Geographical Location of Headquarters
4.2.5. Analysis by Geographical Location of Manufacturing Facilities
4.2.6. Analysis by Scale of Production
4.2.7. Analysis by Application Area
4.2.8. Analysis by Type of Radioisotope
4.2.8.1. Radioisotopes for Diagnostic Use
4.2.8.2. Radioisotopes for Therapeutic Use

4.2.9 Analysis by Target Therapeutic Area
4.2.10 Analysis by Service(s) Offered

5. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (NON-INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Purpose of Production
5.2.3. Analysis by Geographical Location of Manufacturing Facilities
5.2.4. Analysis by Scale of Production
5.2.5. Analysis by Application Area
5.2.6. Analysis by Type of Radioisotopes
5.2.6.1. Radioisotopes for Diagnostic Use
5.2.6.2. Radioisotopes for Therapeutic Use

6. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Cardinal Health
6.2.1. Company Overview
6.2.2. List of Products and Manufacturing Facilities
6.2.3. Recent Developments and Future Outlook 

6.3. GE Healthcare
6.3.1. Company Overview
6.3.2. List of Products and Manufacturing Facilities
6.3.3. Recent Developments and Future Outlook 

6.4. Jubilant Radiopharma
6.4.1. Company Overview
6.4.2. List of Products and Manufacturing Facilities
6.4.3. Recent Developments and Future Outlook 

6.5. Lantheus Medical Imaging
6.5.1. Company Overview
6.5.2. List of Products and Manufacturing Facilities
6.5.3. Recent Developments and Future Outlook 

6.6. Nordion
6.6.1. Company Overview
6.6.2. List of Products and Manufacturing Facilities
6.6.3. Recent Developments and Future Outlook 

6.7. SOFIE
6.7.1. Company Overview
6.7.2. List of Products and Manufacturing Facilities
6.7.3. Recent Developments and Future Outlook 

7. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN EUROPE
7.1. Chapter Overview
7.2. Advanced Accelerator Applications
7.2.1. Company Overview
7.2.2. List of Products and Manufacturing Facilities
7.2.3. Recent Developments and Future Outlook 

7.3. SCK•CEN
7.3.1. Company Overview
7.3.2. List of Products and Manufacturing Facilities
7.3.3. Recent Developments and Future Outlook 

7.4. Curium Pharma
7.4.1. Company Overview
7.4.2. List of Products and Manufacturing Facilities
7.4.3. Recent Developments and Future Outlook 

7.5. Eckert & Ziegler
7.5.1. Company Overview
7.5.2. List of Products and Manufacturing Facilities
7.5.3. Recent Developments and Future Outlook 

7.6. PETNET Solutions
7.6.1. Company Overview
7.6.2. List of Products and Manufacturing Facilities
7.6.3. Recent Developments and Future Outlook 

8. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN ASIA-PACFIC AND REST OF THE WORLD
8.1. Chapter Overview
8.2. China Isotope & Radiation Corporation
8.2.1. Company Overview
8.2.2. List of Products and Manufacturing Facilities
8.2.3. Recent Developments and Future Outlook 

8.3. DuChemBio
8.3.1. Company Overview
8.3.2. List of Products and Manufacturing Facilities
8.3.3. Recent Developments and Future Outlook 

8.4. Eczacibasi-Monrol
8.4.1. Company Overview
8.4.2. List of Products and Manufacturing Facilities
8.4.3. Recent Developments and Future Outlook 

8.5. Nihon Medi-Physics
8.5.1. Company Overview
8.5.2. List of Products and Manufacturing Facilities
8.5.3. Recent Developments and Future Outlook 

8.6. Sinotau Pharmaceuticals
8.6.1. Company Overview
8.6.2. List of Products and Manufacturing Facilities
8.6.3. Recent Developments and Future Outlook 

9. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Assumptions and Key Parameters
9.4. Four-Dimensional Bubble Analysis based on Supplier Power, Product Portfolio Strength and Manufacturing Capabilities
9.4.1. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
9.4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
9.4.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Type of Partnership
10.3.2. Analysis by Year of Partnership
10.3.3. Analysis by Type of Radioisotope
10.3.4. Analysis by Target Therapeutic Area Mentioned in the Agreement
10.3.5. Analysis by Application Mentioned in the Agreement
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. PRODUCTION AND SUPPLY CHAIN OF MEDICAL ISOTOPE MOLYBDENUM-99 (TECHNETIUM-99M)
11.1. Chapter Overview
11.2. Production and Use of Mo-99
11.2.1. Reactor-based Production
11.2.2. Accelerator-based Production

11.3. Supply Chain of Mo-99
11.3.1. Target Suppliers
11.3.2. Irradiation Service Providers
11.3.3. Mo-99 Suppliers
11.3.4. Technetium Generator Suppliers
11.3.5. Tc-99m End-Users

11.4. Future Prospects

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030
12.3.1. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area
12.3.2. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area
12.3.3. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals
12.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals
12.3.5. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production
12.3.6. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions

13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview

14.2. Shertech Laboratories
14.2.1. Company Snapshot
14.2.2. Interview Transcript: James Davis, Vice President Quality / R&D

14.3. University of Ioannina
14.3.1. Organization Snapshot
14.3.2. Interview Transcript: Andreas Fotopoulos, Professor of Nuclear Medicine

14.4. University Medical Center Groningen
14.4.1. Organization Snapshot
14.4.2. Interview Transcript: Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician

14.5. Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
14.5.1. Organization Snapshot
14.5.2. Interview Transcript: Michael van Dam, Professor

14.6. ITM Isotopen Technologien München
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Anonymous

15. APPENDIX 1:  TABULATED DATA 

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures 

Figure 3.1 Structure of a Radiopharmaceuticals Product
Figure 3.2 Production of Radiopharmaceuticals: Radionuclide Generator
Figure 3.3 Production of Radiopharmaceuticals: Particle Accelerator (Cyclotron)
Figure 3.4 Production of Radiopharmaceuticals: Nuclear Reactor
Figure 3.5 Geographical Distribution of Regulatory Bodies Governing the Production of Radiopharmaceuticals
Figure 3.6 Selecting a CMO Partner for Radiopharmaceuticals Production: Parameters to Consider
Figure 4.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Cumulative Distribution by Year of Establishment
Figure 4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Purpose of Production
Figure 4.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Figure 4.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Geographical Location of Headquarters
Figure 4.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
Figure 4.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Scale of Production
Figure 4.9 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Scale of Production
Figure 4.10 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Application Area
Figure 4.11 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Diagnostic Radioisotopes
Figure 4.12 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Therapeutic Radioisotopes
Figure 4.13 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Target Therapeutic Area
Figure 4.14 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Service(s) Offered
Figure 5.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Cumulative Distribution by Year of Establishment
Figure 5.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Purpose of Production
Figure 5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continent-wise)
Figure 5.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Country-wise)
Figure 5.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Scale of Production
Figure 5.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 5.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radioisotopes
Figure 5.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radioisotopes
Figure 9.1 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
Figure 9.2 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
Figure 9.3 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World
Figure 10.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2017-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Radioisotope
Figure 10.4 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Figure 10.5 Partnerships and Collaborations: Distribution by Application Mentioned in the Agreement
Figure 10.3 Most Active Players: Distribution by Number of Partnerships
Figure 10.4 Partnerships and Collaborations: Geographical Distribution
Figure 10.5 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.2 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area (USD Billion)
Figure 12.3 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area (USD Billion)
Figure 12.4 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals (USD Billion)
Figure 12.5 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals (USD Billion)
Figure 12.6 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production (USD Million)
Figure 12.7 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions (USD Million)

List Of Tables

Table 3.1 List of Commonly Used SPECT Radionuclides
Table 3.2 List of Commonly Used PET Radionuclides
Table 3.3 List of Commonly Used Radionuclides for Therapeutic Applications
Table 3.4 List of Generator, Particle Accelerator (Cyclotron) and Reactor Produced Radionuclides
Table 3.5 List of FDA Approved Radiopharmaceuticals
Table 4.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Industry Players
Table 4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Location of Manufacturing Facilities and Scale of Production
Table 4.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Application Area
Table 4.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Diagnostic Radioisotopes
Table 4.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Therapeutic Radioisotopes
Table 4.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Target Therapeutic Area
Table 4.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Service(s) Offered
Table 5.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Non-Industry Players
Table 5.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Scale of Production
Table 5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Application Area
Table 5.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Diagnostic Radioisotopes
Table 5.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Therapeutic Radioisotopes
Table 6.1 Cardinal Health: Company Snapshot
Table 6.2 Cardinal Health: Products and Manufacturing Facilities
Table 6.3 Cardinal Health: Recent Developments and Future Outlook
Table 6.4 GE Healthcare: Company Snapshot
Table 6.5 GE Healthcare: Products and Manufacturing Facilities
Table 6.6 GE Healthcare: Recent Developments and Future Outlook
Table 6.7 Jubilant Radiopharma: Company Snapshot
Table 6.8 Jubilant Radiopharma: Products and Manufacturing Facilities
Table 6.9 Jubilant Radiopharma: Recent Developments and Future Outlook
Table 6.10 Lantheus Medical Imaging: Company Snapshot
Table 6.11 Lantheus Medical Imaging: Products and Manufacturing Facilities
Table 6.12 Lantheus Medical Imaging: Recent Developments and Future Outlook
Table 6.13 Nordion: Company Snapshot
Table 6.14 Nordion: Products and Manufacturing Facilities
Table 6.15 Nordion: Recent Developments and Future Outlook
Table 6.16 SOFIE: Company Snapshot
Table 6.17 SOFIE: Products and Manufacturing Facilities
Table 6.18 SOFIE: Recent Developments and Future Outlook
Table 7.1 Advanced Accelerator Applications: Company Snapshot
Table 7.2 Advanced Accelerator Applications: Products and Manufacturing Facilities
Table 7.3 Advanced Accelerator Applications: Recent Developments and Future Outlook
Table 7.4 SCK•CEN: Company Snapshot
Table 7.5 SCK•CEN: Products and Manufacturing Facilities
Table 7.6 SCK•CEN: Recent Developments and Future Outlook
Table 7.7 Curium Pharma: Company Snapshot
Table 7.8 Curium Pharma: Products and Manufacturing Facilities
Table 7.9 Curium Pharma: Recent Developments and Future Outlook
Table 7.10 Eckert & Ziegler: Company Snapshot
Table 7.11 Eckert & Ziegler: Products and Manufacturing Facilities
Table 7.12 Eckert & Ziegler: Recent Developments and Future Outlook
Table 7.13 PETNET Solutions: Company Snapshot
Table 7.14 PETNET Solutions: Products and Manufacturing Facilities
Table 7.15 PETNET Solutions: Recent Developments and Future Outlook
Table 8.1 China Isotope & Radiation Corporation: Company Snapshot
Table 8.2 China Isotope & Radiation Corporation: Products and Manufacturing Facilities
Table 8.3 China Isotope & Radiation Corporation: Recent Developments and Future Outlook
Table 8.4 DuChemBio: Company Snapshot
Table 8.5 DuChemBio: Products and Manufacturing Facilities
Table 8.6 DuChemBio: Recent Developments and Future Outlook
Table 8.7 Eczacibasi-Monrol: Company Snapshot
Table 8.8 Eczacibasi-Monrol: Products and Manufacturing Facilities
Table 8.9 Eczacibasi-Monrol: Recent Developments and Future Outlook
Table 8.10 Nihon Medi-Physics: Company Snapshot
Table 8.11 Nihon Medi-Physics: Products and Manufacturing Facilities
Table 8.12 Nihon Medi-Physics: Recent Developments and Future Outlook
Table 8.13 Sinotau Pharmaceuticals: Company Snapshot
Table 8.14 Sinotau Pharmaceuticals: Products and Manufacturing Facilities
Table 8.15 Sinotau Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1 Nuclear Medicines and Radiopharmaceuticals Manufacturing: List of Partnerships and Collaborations
Table 15.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Cumulative Distribution by Year of Establishment
Table 15.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players) Distribution by Company Size
Table 15.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Purpose of Production
Table 15.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Table 15.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Table 15.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Geographical Location of Headquarters
Table 15.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
Table 15.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Scale of Production
Table 15.9 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Scale of Production
Table 15.10 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Application Area
Table 15.11 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Diagnostic Radioisotopes
Table 15.12 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Therapeutic Radioisotopes
Table 15.13 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Target Therapeutic Area
Table 15.14 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Service(s) Offered
Table 15.15 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Cumulative Distribution by Year of Establishment
Table 15.16 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Purpose of Production
Table 15.17 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continent-wise)
Table 15.18 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Country-wise)
Table 15.19 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Scale of Production
Table 15.20 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Application Area
Table 15.21 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radioisotopes
Table 15.22 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radioisotopes
Table 15.23 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2017-2020
Table 15.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.25 Partnerships and Collaborations: Distribution by Type of Radioisotope
Table 15.26 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Table 15.27 Partnerships and Collaborations: Distribution by Application Area
Table 15.28 Most Active Players: Distribution by Number of Partnerships
Table 15.29 Partnerships and Collaborations: Geographical Distribution
Table 15.30 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.31 Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.32 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Target Therapeutic Area (USD Billion)
Table 15.33 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Application Area (USD Billion)
Table 15.34 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals (USD Billion)
Table 15.35 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals (USD Billion)
Table 15.36 Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Purpose of Production (USD Million)
Table 15.37 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Key Geographical Regions (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3D Imaging Drug Design and Development
  2. ABX advanced biochemical compounds
  3. Abzena
  4. Advanced Accelerator Applications
  5. Advanced Nuclear Medicine Ingredients
  6. Ahmanson Translational Imaging Division
  7. Alliance Medical
  8. Alpha Tau
  9. Arronax
  10. ARTMS Products
  11. ASAN Medical Center
  12. Atlab Pharma
  13. ATONCO
  14. Australian Nuclear Science and Technology Organisation
  15. Avid Radiopharmaceuticals
  16. Bar-Ilan University
  17. Bayer
  18. Biomedical Research Imaging Center, UNC School of Medicine
  19. Bio-Nucleonics
  20. Blue Earth Diagnostics
  21. Board of Radiation and Isotope Technology
  22. Bracco Diagnostics
  23. Bruce Power
  24. BWX Technologies
  25. Cameco
  26. Canadian Nuclear Isotope Council
  27. Cancer Targeted Technology
  28. Cardinal Health
  29. Center for Molecular and Genomic Imaging, UC Davis
  30. Center for Neurosciences, The Feinstein Institute
  31. Center for Radiochemistry Research, OHSU Knight Cardiovascular Institute
  32. Center for Systems Imaging Core, Emory University
  33. Centre for Advanced Imaging, The University of Queensland
  34. Centre for In Vivo Imaging, Newcastle University
  35. Centre for Probe Development and Commercialization
  36. Cerveau Technologies
  37. Chengdu Gaotong Isotope
  38. Chengdu New Radiomedicine Technology
  39. China Isotope & Radiation Corporation
  40. Clinical Imaging Research Centre, National University of Singapore
  41. Crump Cyclotron and Radiochemistry Technology Center,University of California
  42. Curium Pharma
  43. Cyclopharma
  44. Cyclotek
  45. Cyclotope Radiopharmacy
  46. Cyclotron & Radiochemistry Facility, Stanford University School of Medicine
  47. Cyclotron and Radiochemistry Facility, Citigroup Biomedical Imaging Center of Weill Cornell Medicine
  48. Cyclotron and Radiochemistry Facility, UT Southwestern Medical Center
  49. Cyclotron and Radiochemistry Laboratories, Keck School of Medicine of USC
  50. Cyclotron and Radiopharmaceutical Core, Houston Methodist Research Institute
  51. Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre
  52. Cyclotron Facility, University  of Chicago
  53. Cyclotron Radiochemistry Facility, MD Anderson Cancer Center
  54. Department of Molecular and Medical Pharmacology, University of California
  55. Department of Nuclear Medicine and PET, Liverpool Hospital
  56. Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
  57. Department of Nuclear Medicine, School of Health Sciences, University of Ioannina
  58. Department of Radiology & Biomedical Imaging, University of California
  59. Department of Radiology, The University of Alabama at Birmingham
  60. Department of Radiology, University of Colorado
  61. Department of Radioplogy, Penn Medicine, University of Pennsylvania
  62. Dongcheng Biochemicals
  63. DuChemBio
  64. Eckert & Ziegler
  65. Eczacibasi-Monrol
  66. Endocyte
  67. Essential Isotopes
  68. Framatome
  69. FUJIFILM Toyama Chemical
  70. FutureChem
  71. GE Healthcare
  72. GE Hitachi Nuclear Energy 
  73. Global Medical Solutions
  74. Global Morpho Pharma
  75. Grupo RPH
  76. HealthTrust
  77. Heidelberg Pharma
  78. Heidelberg University Hospital 
  79. Huntsman Cancer Institute Center for Quantitative Cancer Imaging, Univeristy of Utah Health
  80. IASON
  81. ImaginAb
  82. Imaging Facilities, The University of Manchester
  83. Inserm
  84. Institut National des Radioéléments
  85. Institute for Energy Technology
  86. Institute of Applied Radiopharmacy of Barcelona
  87. Institute of Isotopes (IZOTOP)
  88. Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf 
  89. International Isotopes
  90. IRE ELiT- Radiopharmaceuticals
  91. Iso-Tex Diagnostics
  92. IsoTherapeutics
  93. Isotopia Molecular Imaging
  94. Itelpharma
  95. iThemba LABS
  96. ITM Isotopen Technologien München
  97. Jubilant Radiopharma
  98. Kinectrics
  99. Korea Insititute of Radiological & Medical Sciences
  100. Kresge Cyclotron/PET Facility, Department of Radiology, University of Michigan
  101. Lantheus Medical Imaging
  102. Life Molecular Imaging
  103. Macquarie University 
  104. Mallinckrodt Institute of Radiology, PET Nuclear Pharmacy and Cyclotron Facility, Washington University
  105. Mallinckrodt Nuclear Imaging
  106. Map Medical Technologies
  107. Mayo Clinic
  108. McMaster University Cyclotron Facility
  109. Medi-Radiopharma
  110. Memorial Sloan Kettering Cancer Center
  111. Merck
  112. Micro-Rad
  113. Molecular Imaging Institute (M2i)
  114. NanoMab Technology
  115. National Centre for Nuclear Research Radioisotope Centre (POLATOM)
  116. NCMUSA
  117. Nihon Medi-Physics
  118. Ningbo Junan Pharmaceuticals Technology
  119. Nordal Cyclotron & PET Radiochemistry,  Lawson Health Research Institute
  120. Nordic Nanovector
  121. Nordion
  122. Norsk Medisinsk 
  123. Novartis
  124. NTP Radioisotopes
  125. Nuclear and Energy Research Institute
  126. Nuclear Medicine and Molecular Imaging, University of Groningen
  127. Nuclear Medicine/Biomedical Imaging Research Core, Brigham and Women's Hospital
  128. Nuclear Research Institute Rez
  129. Nucleis Radiopharmaceuticals
  130. OncoBeta
  131. Ontario Power Generation
  132. PET Center, Columbia University
  133. PET Core, Gordan Center for Medical Imaging, Harvard Medical School
  134. PET Pharm Biotech
  135. PET Radiochemistry and Radiopharmacy, University of Oxford
  136. PET Research Core, Renaissance School of Medicine, Stony Brook University
  137. PET Research Facility, Wake Forest School of Medicine
  138. PET Research Radiochemistry, University of Ottawa
  139. PETNET Solutions
  140. PetTecH Solutions
  141. Piramal Imaging
  142. PositronPharma
  143. Premier
  144. Progenics Pharmaceuticals
  145. Q BioMed
  146. Radboud University Medical Center
  147. Radiochemistry & Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center
  148. Radiochemistry Core, University of Virginia
  149. Radiochemistry Core, Vanderbilt University Institute of Imaging Science
  150. Radiochemistry Facility, Loma Linda University
  151. Radiochemistry Unit, University of Helsinki 
  152. RadioMedix
  153. Radiopharmaceutical Core Facility, Case Western Reserve University 
  154. Radiopharmazeutische Wissenschaften, Division of Nuclear Medicine at the Medical University of Vienna
  155. RadLink Asia
  156. Research Imaging Institute, University of Teaxs Health Science Center
  157. Rosatom State Atomic Energy Corporation
  158. ROTOP Pharmaka
  159. Saskatchewan Centre for Cyclotron Sciences
  160. SCK•CEN
  161. Seibersdorf Laboratories
  162. Shertech Nuclear
  163. Sinotau Pharmaceutical
  164. Societatea Nationala Nuclearelectrica
  165. SOFIE
  166. SpectronRx
  167. SWAN Isotopen
  168. Techna Institute
  169. Telix Pharmaceuticals
  170. The McConnell Brain Imaging Centre, University of McGrill
  171. Theragnostics
  172. Therapeia
  173. Thunder Bay Cyclotron and Radiochemistry Laboratories, Lakehead University
  174. Tong Xing
  175. Toyama Chemical
  176. Triad Isotopes
  177. Turku PET Centre
  178. United Imaging Healthcare
  179. University of Melbourne
  180. University of Missouri
  181. University of Washington Radiochemistry Resources
  182. USC Molecular Imaging Center, University of Southern California
  183. Vect-Horus
  184. Westinghouse Partners
  185. Wolfson Brain Imaging Centre, University of Cambridge
  186. Xcision
  187. Y-mAbs Therapeutics
  188. Zevacor Molecular
  189. Zionexa

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com